{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:16:21Z","timestamp":1793740581606,"version":"4.6.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although the criteria for acute migraine treatment and prevention have been well described, there are still unmet needs, general underuse and low benefits of preventive drugs.<\/jats:p>\n                    <jats:p>The aim of the present study was to retrospectively observe the short-term effect of preventive treatment in a cohort of migraine patients attending a tertiary headache center, using data from electronic medical records.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was an observational retrospective cohort study based on data collected in a tertiary headache center. Data were extracted from an electronic dataset collected from January 2009 to December 2019. The main selection criteria were as follows: age of 18\u201375\u2009years; diagnosis of migraine without aura (MO), migraine with aura (MA) or chronic migraine (CM); a control visit 3 months after the first access; and prescription of preventive treatment with level of evidence 1 as reported by Italian guidelines. As the primary outcome, we considered the change in the frequency of headache at the follow-up visit. Then, as secondary outcome measures, we used disability scores, intensity of headache, and allodynia. As predictive factors, we considered age, migraine duration, sex, headache frequency, allodynia, anxiety and depression at baseline, and comorbidity with fibromyalgia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 6430 patients screened, 2800 met the selection criteria, 1800 returned to the follow-up visit, 550 withdrew because of adverse events, and 1100 were included the analysis. One hundred thirty-four patients had a frequency reduction of 50% or more. Flunarizine was used for less severe migraine, with a better effect compared to those of other drugs (odds ratio: 1.48; p: 0.022). Low headache frequency and absent or mild allodynia predicted a better outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The mild effect of preventive drugs on migraine features and even the number of patients who were lost to follow-up or dropped out because of adverse events confirm that in severe and chronic patients, the first line of prevention can only delay a more focused therapeutic approach.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-020-01839-5","type":"journal-article","created":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T04:03:48Z","timestamp":1593230628000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Failure of preventive treatments in migraine: an observational retrospective study in a tertiary headache center"],"prefix":"10.1186","volume":"20","author":[{"given":"Marianna","family":"Delussi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Vecchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Libro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Quitadamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6567-5373","authenticated-orcid":false,"given":"Marina","family":"de Tommaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,30]]},"reference":[{"key":"1839_CR1","unstructured":"World Health Organization (WHO). Disease burden and mortality estimates.2018.http:\/\/who.int\/healthinfo\/global_burden_disease\/estimates\/en\/index1. html. Accessed 20 May 201."},{"issue":"Suppl 2","key":"1839_CR2","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1007\/s10194-012-0437-6","volume":"13","author":"P Sarchielli","year":"2012","unstructured":"Sarchielli P, Granella F, Prudenzano MP, et al. Italian guidelines for primary headaches: 2012 Revised version. J Headache Pain. 2012;13(Suppl 2):S31\u201370.","journal-title":"J Headache Pain"},{"issue":"1","key":"1839_CR3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s10194-019-1027-7","volume":"20","author":"C Piccinni","year":"2019","unstructured":"Piccinni C, Cevoli S, Ronconi G, et al. A real-world study on unmet medical needs in triptan-treated migraine: prevalence, preventive therapies and triptan use modification from a large Italian population along two years. J Headache Pain. 2019;20(1):74.","journal-title":"J Headache Pain."},{"issue":"1","key":"1839_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/03007995.2019.1657716","volume":"36","author":"JH Ford","year":"2020","unstructured":"Ford JH, Schroeder K, Buse DC, et al. Predicting initiation of preventive migraine medications: exploratory study in a large U.S. medical claims database. Curr Med Res Opin. 2020;36(1):51\u2013614.","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"1839_CR5","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1177\/0333102409355661","volume":"30","author":"D Valade","year":"2010","unstructured":"Valade D, Lant\u00e9ri-Minet M, Radat F, et al. Clinical determinants of migraine preventive treatment: contribution of SMILE, an observational survey of primary care migraine management in France. Cephalalgia. 2010;30(10):1207\u201313.","journal-title":"Cephalalgia."},{"issue":"6","key":"1839_CR6","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","volume":"14","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338\u201350.","journal-title":"Nat Rev Neurol"},{"issue":"1\u20132","key":"1839_CR7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000499764","volume":"81","author":"M de Tommaso","year":"2019","unstructured":"de Tommaso M, Brighina F, Delussi M. Effects of Botulinum toxin a on Allodynia in chronic migraine: an observational open-label two-year study. Eur Neurol. 2019;81(1\u20132):37\u201346.","journal-title":"Eur Neurol"},{"issue":"Suppl. 1","key":"1839_CR8","first-page":"24","volume":"24","author":"Headache Classification Subcommittee of International headache Society","year":"2004","unstructured":"Headache Classification Subcommittee of International headache Society. The international classification of headache disorders, 2nd edition. Cephalalgia. 2004;24(Suppl. 1):24\u201336.","journal-title":"Cephalalgia."},{"issue":"1","key":"1839_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society. (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society. (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1\u2013211.","journal-title":"Cephalalgia."},{"key":"1839_CR10","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1046\/j.0333-1024.2001.00277.x","volume":"21","author":"D D\u2019Amico","year":"2001","unstructured":"D\u2019Amico D, Mosconi P, Genco S, Usai S, Prudenzano AM, Grazzi L, Leone M, Puca FM, Bussone G. The migraine disability assessment (MIDAS) questionnaire: translation and reliability of the Italian version. Cephalalgia. 2001;21:947\u201352.","journal-title":"Cephalalgia"},{"key":"1839_CR11","first-page":"235","volume-title":"Measuring functioning and well-being: the medical outcomes study approach","author":"RD Hays","year":"1992","unstructured":"Hays RD, Stewart A. Sleep measures. In: Stewart A, Ware J, editors. Measuring functioning and well-being: the medical outcomes study approach. Durham: Duke University Press; 1992. p. 235\u201359."},{"key":"1839_CR12","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/archpsyc.1965.01720310065008","volume":"12","author":"WW Zung","year":"1965","unstructured":"Zung WW. A self-rating depression scale. Arch Gen Psychiatry. 1965;12:63\u201370.","journal-title":"Arch Gen Psychiatry"},{"key":"1839_CR13","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S0033-3182(71)71479-0","volume":"12","author":"WW Zung","year":"1971","unstructured":"Zung WW. A rating instrument for anxiety disorders. Psychosomatics. 1971;12:371\u20139.","journal-title":"Psychosomatics"},{"issue":"2","key":"1839_CR14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2174\/1573397112666151231110813","volume":"12","author":"M de Tommaso","year":"2016","unstructured":"de Tommaso M, Sciruicchio V. Migraine and central sensitization: clinical features, Main comorbidities and therapeutic perspectives. Curr Rheumatol Rev. 2016;12(2):113\u201326.","journal-title":"Curr Rheumatol Rev"},{"key":"1839_CR15","doi-asserted-by":"crossref","unstructured":"Cevoli S, D'Amico D, Martelletti P, et al. Underdiagnosis and undertreatment of migraine in Italy: a survey of patients attending for the first time 10 headache centres. Cephalalgia. 2009 ;29(12):1285\u201393.","DOI":"10.1111\/j.1468-2982.2009.01874.x"},{"issue":"10","key":"1839_CR16","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1111\/head.13202","volume":"57","author":"JH Ford","year":"2017","unstructured":"Ford JH, Jackson J, Milligan G, Cotton S, Ahl J, Aurora SK. A real-world analysis of migraine: a cross-sectional study of disease burden and treatment patterns. Headache. 2017;57(10):1532\u201344.","journal-title":"Headache."},{"issue":"6","key":"1839_CR17","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0333102414547138","volume":"35","author":"Z Hepp","year":"2015","unstructured":"Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35(6):478\u201388.","journal-title":"Cephalalgia"},{"issue":"1","key":"1839_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s10194-018-0899-2","volume":"20","author":"TJ Steiner","year":"2019","unstructured":"Steiner TJ, Jensen R, Katsarava Z, et al. Aids to management of headache disorders in primary care (2nd edition) : on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache. J Headache Pain. 2019;20(1):57.","journal-title":"J Headache Pain"},{"key":"1839_CR19","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1093\/ije\/24.3.612","volume":"24","author":"MB Russell","year":"1995","unstructured":"Russell MB, Rasmussen BK, Thorvaldsen P, Olesen J. Prevalence and sex-ratio of the subtypes of migraine. Int J Epidemiol. 1995;24:612\u20137.","journal-title":"Int J Epidemiol"},{"issue":"Suppl 1","key":"1839_CR20","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1007\/s10072-008-0884-7","volume":"29","author":"GC Manzoni","year":"2008","unstructured":"Manzoni GC, Torelli P. Migraine with and without aura: a single entity? Neurol Sci. 2008;29(Suppl 1):S40\u20133.","journal-title":"Neurol Sci"},{"issue":"1","key":"1839_CR21","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s10194-019-1038-4","volume":"20","author":"EC Agostoni","year":"2019","unstructured":"Agostoni EC, Barbanti P, Calabresi P, et al. Current and emerging evidence-based treatment options in chronic migraine: a narrative review. J Headache Pain. 2019;20(1):92.","journal-title":"J Headache Pain."},{"issue":"1","key":"1839_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s10194-019-0971-6","volume":"20","author":"D Garc\u00eda-Azorin","year":"2019","unstructured":"Garc\u00eda-Azorin D, Santos-Lasaosa S, Gago-Veiga AB, Viguera Romero J, Guerrero-Peral AL. Real world preventative drug management of migraine among Spanish neurologists. J Headache Pain. 2019;20(1):19.","journal-title":"J Headache Pain."},{"issue":"4 Headache","key":"1839_CR23","first-page":"1018","volume":"21","author":"SJ Tepper","year":"2015","unstructured":"Tepper SJ. Nutraceutical and Other Modalities for the Treatment of Headache. Continuum (Minneap Minn). 2015;21(4 Headache):1018\u201331.","journal-title":"Continuum (Minneap Minn)"},{"issue":"1","key":"1839_CR24","first-page":"E97","volume":"19","author":"HY Chiu","year":"2016","unstructured":"Chiu HY, Yeh TH, Huang YC, Chen PY. Effects of intravenous and Oral magnesium on reducing migraine: a meta-analysis of randomized controlled trials. Pain Physician. 2016;19(1):E97\u2013E112.","journal-title":"Pain Physician"},{"issue":"1","key":"1839_CR25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.18553\/jmcp.2014.20.1.22","volume":"20","author":"Z Hepp","year":"2014","unstructured":"Hepp Z, Bloudek LM, Varon SF. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm. 2014;20(1):22\u201333.","journal-title":"J Manag Care Pharm"},{"issue":"1","key":"1839_CR26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s10194-018-0946-z","volume":"19","author":"P Martelletti","year":"2018","unstructured":"Martelletti P, Schwedt TJ, Lanteri-Minet M, et al. My migraine voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. J Headache Pain. 2018;19(1):115.","journal-title":"J Headache Pain."},{"issue":"11","key":"1839_CR27","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s11916-019-0823-8","volume":"23","author":"T Dorosch","year":"2019","unstructured":"Dorosch T, Ganzer CA, Lin M, Seifan A. Efficacy of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the preventative treatment of episodic migraine in adults. Curr Pain Headache Rep. 2019;23(11):85.","journal-title":"Curr Pain Headache Rep"},{"issue":"3","key":"1839_CR28","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1046\/j.1468-2982.2002.t01-1-00309.x","volume":"22","author":"HC Diener","year":"2002","unstructured":"Diener HC, Matias-Guiu J, Hartung E, Pfaffenrath V, Ludin HP, Nappi G, De Beukelaar F. Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160 mg daily. Cephalalgia. 2002;22(3):209\u201321.","journal-title":"Cephalalgia"},{"issue":"7","key":"1839_CR29","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1097\/AJP.0b013e31826b130f","volume":"29","author":"UK Misra","year":"2013","unstructured":"Misra UK, Kalita J, Bhoi SK. Allodynia in migraine: clinical observation and role of prophylactic therapy. Clin J Pain. 2013;29(7):577\u201382.","journal-title":"Clin J Pain"},{"issue":"2","key":"1839_CR30","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/j.1526-4610.2012.02279.x","volume":"53","author":"A Raggi","year":"2013","unstructured":"Raggi A, Leonardi M, Bussone G, D'Amico D. A 3-month analysis of disability, quality of life, and disease course in patients with migraine. Headache. 2013;53(2):297\u2013309.","journal-title":"Headache."},{"issue":"7","key":"1839_CR31","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1111\/head.13115","volume":"57","author":"RB Lipton","year":"2017","unstructured":"Lipton RB, Munjal S, Buse DC, et al. Allodynia is associated with initial and sustained response to acute migraine treatment: results from the American Migraine Prevalence and Prevention study. Headache. 2017;57(7):1026\u201340.","journal-title":"Headache."},{"issue":"5","key":"1839_CR32","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1177\/0333102411434811","volume":"32","author":"T Ferrante","year":"2012","unstructured":"Ferrante T, Castellini P, Abrignani G, et al. The PACE study: past-year prevalence of migraine in Parma's adult general population. Cephalalgia. 2012;32(5):358\u201365.","journal-title":"Cephalalgia."},{"issue":"9","key":"1839_CR33","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1111\/head.13407","volume":"58","author":"RB Lipton","year":"2018","unstructured":"Lipton RB, Munjal S, Alam A, et al. Migraine in America symptoms and treatment (MAST) study: baseline study methods, treatment patterns, and gender differences. Headache. 2018;58(9):1408\u201326.","journal-title":"Headache."}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-020-01839-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-020-01839-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-020-01839-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T19:20:15Z","timestamp":1624994415000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-020-01839-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,30]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1839"],"URL":"https:\/\/doi.org\/10.1186\/s12883-020-01839-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-25315\/v1","asserted-by":"object"}]},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,30]]},"assertion":[{"value":"16 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The local Ethics Committee of Policlinico General Hospital approved the use of the electronic database, and patients signed an informed consent form about the inclusion of their data and use for scientific purposes.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No authors declare any conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"256"}}